Molecular imaging firm Blue Earth Diagnostics has signed a new manufacturing and distribution agreement with Irish firm M2i for its Axumin (fluciclovine F-18) PET agent.
Privately owned M2i has supplied PET imaging agents to facilities across the Republic of Ireland since 2001, Blue Earth said. It will manufacture Axumin at its Dublin site and bring the agent to market in both the Republic of Ireland and Northern Ireland.
Axumin is cleared in Europe to detect recurrence of prostate cancer in adult men, and is the first PET imaging agent approved for that purpose by the European Commission, according to Blue Earth.
